Eli Lilly and Company

Eli Lilly and Company Earnings Recaps

LLY Health Care 3 recaps
Next earnings: February 10, 2027 (estimated) · full calendar
Q3 2026 Oct 30, 2026

Lilly shares rose 6.5% after Q3 revenue grew 39% and the company raised full-year financial guidance. The headline growth was tempered by lower realized prices and roughly $900 million of one-time or estimate-related revenue benefits.

Key takeaways
  • Revenue increased 39% year over year; gross margin rose 80 basis points to 84.4%, while the non-GAAP performance margin reached 54.2%, up 5.9 percentage points.
  • Non-GAAP EPS was $7.48, including $4.57 of acquired IPR&D charges; the prior-year quarter was $7.20, including $0.71 of such charges.
  • U.S. revenue grew 34%, primarily on Mounjaro and Zepbound volume, but U.S. price declined 7%—or 10% excluding a favorable rebate-and-discount estimate adjustment.
  • Q3 revenue benefited by approximately $900 million from previously noted items, including a $410 million one-time milestone payment in Europe and the U.S. estimate adjustment.
  • Lilly raised full-year financial guidance; the call also cited continued product launches and pipeline investment, with R&D expense up 23% year over year.
Q2 2026 Aug 7, 2026

Lilly’s Q2 revenue growth and margin expansion outpaced expectations, driven by strong volume gains in key products like Mounjaro and Zepbound, pushing the stock up 6.8%. The market clearly rewarded the company’s robust commercial execution and positive pipeline developments.

Key takeaways
  • Revenue surged 48% year-over-year, fueled primarily by volume growth of Mounjaro, Zepbound, and contributions from Immunology, Oncology, and Neuroscience portfolios.
  • Gross margin improved to 86.3%, a 1.3 percentage point increase, reflecting favorable product mix and better production costs.
  • U.S. pricing declined 3% overall, or 9% excluding rebate and discount estimate adjustments, but volume growth offset price pressure.
  • Non-GAAP EPS rose to $8.38, including $3.03 in acquired intangible asset charges, compared to $6.31 last year (with $0.14 in charges).
  • Regulatory and commercial progress included approvals for Ebglyss maintenance dosing, Jaypirca expansions, and Foundayo launches in multiple international markets, supporting future growth prospects.
Q1 2026 May 1, 2026

Eli Lilly shares surged 13.2% post-earnings as the company delivered standout top-line growth, marked by a 56% YoY revenue increase and strong outperformance from key products. The initial U.S. launch of oral GLP-1 Foundayo further lifted sentiment, signaling investor optimism on future growth drivers.

Key takeaways
  • Revenue grew 56% versus Q1 2025, propelled by blockbuster performance from products like Seman and Monjaro.
  • Non-GAAP earnings per share reached $8.55, up from $3.34 in the prior year quarter.
  • Non-GAAP performance margin expanded by approximately 7 percentage points year-on-year to 50%, despite a 1 percentage point decline in gross margin.
  • The U.S. approval and initial rollout of Foundayo (oral GLP-1 for obesity) marked a significant pipeline milestone, with global regulatory filings underway.
  • The company maintained its pipeline momentum, announcing multiple positive Phase III results and closing several business development acquisitions, while increasing R&D and SG&A investments to support future growth.